glp 1 vs glp 1 agonist GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease A Closer Look at the

The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor

CagriSema combines semaglutide with cagrilintide , an amylin analog, for potentially enhanced effects

10.1097/RD9.0000000000000131 Reprod Dev Med

Doi: 10.1016/j.cgh.2024.03.013 [DOI] [PubMed] [Google Scholar] 102

Fixed-dose combinations could optimize outcomes, particularly for patients with advanced disease or those unresponsive to monotherapy

Across major trials: Lean mass typically represents 2540% of total weight lost , meaning 6075% is fat loss . Imaging studies suggest tirzepatide may improve muscle quality , reducing fat infiltration within muscle tissueeven as total lean mass declines. A prospective 12-month semaglutide study demonstrated favorable body-composition changes with preserved or improved functional outcomes in some participants. In short: body composition improves , even when the scale shows lean-mass reduction. Muscle Changes by Weight-Loss Method How to Preserve Muscle on Semaglutide or Tirzepatide Protein targets for GLP-1 patients A clinically supported target for preserving lean mass during weight loss is: 1.21.6 g/kg/day ( 0.540.73 g/lb/day ) for most adults Higher intakes approximately 0.71.0 g per pound of body weight per day may be beneficial for individuals performing regular resistance training, particularly during calorie restriction, to better preserve or increase lean mass. Distributing protein across meals (often ~2540 g per meal ) supports muscle protein synthesis. Resistance training 23 per week Resistance training provides the mechanical signal required to retain muscle.